A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy …………… Goemans N, Mercuri E, Belousova E, Komaki H, Dubrovsky A, McDonald CM, Kraus JE, Lourbakos A, Lin Z, Campion G, Wang SX, Campbell C; DEMAND III study group. Neuromuscul Disord. 2017 Dec 1. pii: S0960-8966(17)30200-6. PubMed 00
First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery …………… Pfeiffer N, Voykov B, Renieri G, Bell K, Richter P, Weigel M, Thieme H, Wilhelm B, Lorenz K, Feindor M, Wosikowski K, Janicot M, Päckert D, Römmich R,…
A-To-I Editing of Microrna-487b Alters Target Gene Selection After Ischemia and Promotes Neovascularization …………… van der Kwast RV, van Ingen E, Parma L, Peters HA, Quax PH, Nossent AY. Circ Res. 2017 Dec 28. pii: CIRCRESAHA.117.312345. PubMed 00
Profiling the Mismatch Tolerance of Argonaute 2 through Deep Sequencing of Sliced Polymorphic Viral RNAs …………… Theotokis PI, Usher L, Kortschak CK, Schwalbe E, Moschos SA. Mol Ther Nucleic Acids. 2017 Dec 15;9:22-33. PubMed 00